Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Will $2.5Bn Jury Verdict Against Gilead Stand? Future Royalties, Willful Infringement Penalty Uncertain

Executive Summary

Gilead is appealing a jury finding that it must pay Merck 10% royalty on sales of Sovaldi and Harvoni through August 2016; judge could find the firm owes treble the amount for willful infringement.

You may also be interested in...



Gilead Avoids $2.5bn Jury Verdict As Judge Rules Merck's Hep C Patent Is Invalid

 Merck to appeal decision after district court says Gilead's discovery of sofosbuvir was 'neither routine nor simple.'

After Hep C Patent Battle, Gilead Faces ViiV Suit Over Its New HIV Drug

Complaint says similarities between Gilead's Biktarvy and ViiV's dolutegravir suggest Gilead copied ViiV's drug.

Merck's Write-Down Of Phase II Nuc Illustrates Current Reality In HCV

While a dwindling patient base and pricing pressures are depleting the market opportunity in hepatitis C, Merck's decision also may result from regulatory dialogue potentially delaying the start of a Phase III study.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

PS119695

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel